{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-024005","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.679923+00:00","generated_at":"2026-05-26T23:27:32.568705+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IN8bio Phase 1 INB-100: 100% AML remission at median 20.1 months, 100% 1-year PFS/OS","bullets":["All 9 AML patients remain in complete remission; median follow-up 20.1 months, longest >3 years.","One-year PFS/OS 100% vs historical controls (CIBMTR PFS 67.8%, OS 74.7%).","No cytokine release syndrome or neurotoxicity observed; manageable GvHD in line with historical data.","Patients median age 68, high-risk, including prior CAR-T failures; therapy well-tolerated.","Company to host conference call today at 8:30am ET to discuss data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-024005","json":"https://secwatch.observer/filing/0001193125-25-024005.json","markdown":"https://secwatch.observer/filing/0001193125-25-024005.md","text":"https://secwatch.observer/filing/0001193125-25-024005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525024005/0001193125-25-024005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525024005/d905966d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:27:32.568705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}